ERBB2 and breast cancer: Unlike the situation in breast cancer, diagnosis and treatment in bladder cancer currently still depends on histopathologic evaluations not including IHC based molecular subtyping though certain parameters such as HER2 mRNA expression could be used to distinguish luminal from basal type bladder cancer [5].